Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX opened at $3.85 on Friday. The business has a 50 day simple moving average of $4.26 and a two-hundred day simple moving average of $5.01. The firm has a market capitalization of $50.01 million, a price-to-earnings ratio of 3.26 and a beta of 0.45. Eagle Pharmaceuticals has a one year low of $3.21 and a one year high of $23.52.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in EGRX. Acadian Asset Management LLC raised its position in shares of Eagle Pharmaceuticals by 5.5% in the 3rd quarter. Acadian Asset Management LLC now owns 236,902 shares of the specialty pharmaceutical company’s stock worth $3,733,000 after acquiring an additional 12,326 shares in the last quarter. Brandes Investment Partners LP raised its position in shares of Eagle Pharmaceuticals by 34.9% in the 3rd quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock worth $17,889,000 after acquiring an additional 293,276 shares in the last quarter. Trexquant Investment LP raised its position in shares of Eagle Pharmaceuticals by 26.1% in the 3rd quarter. Trexquant Investment LP now owns 67,187 shares of the specialty pharmaceutical company’s stock worth $1,060,000 after acquiring an additional 13,910 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Eagle Pharmaceuticals by 25.0% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock worth $7,885,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Kennedy Capital Management LLC bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth approximately $575,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.